Literature DB >> 16333653

Effects of the atypical antipsychotics olanzapine and risperidone on plasma prolactin levels in male rats: a comparison with clinical data.

Claire Rourke1, Kathryn R Starr, Charlie Reavill, Sue Fenwick, Kim Deadman, Declan N C Jones.   

Abstract

RATIONALE: Hyperprolactinaemia is a common side effect of antipsychotic treatment and the clinical consequences associated with this, e.g. sexual dysfunction, can have a negative impact on patient compliance.
OBJECTIVES: The aim of this study was to investigate the effect of the atypical antipsychotics olanzapine and risperidone on prolactin levels in rats using different treatment regimes and to compare these data with those reported clinically.
METHODS: All experiments were carried out in male CD rats. In separate studies, the effects of acute, sub-chronic (7 days) and chronic (28 days) olanzapine and risperidone administration on prolactin levels were determined. Further studies investigated the time course of the prolactin response following olanzapine and risperidone treatment over 24 h.
RESULTS: Both drugs significantly increased prolactin levels in a similar manner following acute administration, in keeping with clinically reported data. However, this elevation was still present following sub-chronic and chronic treatment, contrasting with clinical data with respect to olanzapine but not risperidone. Over 24 h, olanzapine demonstrated a more transient elevation of prolactin levels, whereas risperidone caused a robust and persistent increase in prolactin up to 24 h post-dose, closely mimicking clinical results.
CONCLUSIONS: The present study has demonstrated that olanzapine and risperidone display similar effects on prolactin levels in the rat following acute and chronic administration but differ in their prolactin response over a 24-h period. In conclusion, prolactin levels in rats following atypical antipsychotic treatment may not be fully predictive of the clinical situation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16333653     DOI: 10.1007/s00213-005-0230-1

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  36 in total

Review 1.  New antipsychotics and schizophrenia: a review on efficacy and side effects.

Authors:  Alessandro Serretti; Diana De Ronchi; Cristina Lorenzi; Domenico Berardi
Journal:  Curr Med Chem       Date:  2004-02       Impact factor: 4.530

2.  Prolactin levels and adverse events in patients treated with risperidone.

Authors:  D L Kleinberg; J M Davis; R de Coster; B Van Baelen; M Brecher
Journal:  J Clin Psychopharmacol       Date:  1999-02       Impact factor: 3.153

3.  Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats.

Authors:  Manickam Aravagiri; Stephen R Marder
Journal:  Psychopharmacology (Berl)       Date:  2001-11-20       Impact factor: 4.530

Review 4.  Tolerability of atypical antipsychotics.

Authors:  C Stanniland; D Taylor
Journal:  Drug Saf       Date:  2000-03       Impact factor: 5.606

5.  The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations.

Authors:  A M Crawford; C M Beasley; G D Tollefson
Journal:  Schizophr Res       Date:  1997-07-25       Impact factor: 4.939

6.  The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia.

Authors:  S R David; C C Taylor; B J Kinon; A Breier
Journal:  Clin Ther       Date:  2000-09       Impact factor: 3.393

7.  Effects of the atypical antipsychotic olanzapine on reproductive function and weight gain in female rats.

Authors:  M J Fell; K M Marshall; J Williams; J C Neill
Journal:  J Psychopharmacol       Date:  2004-06       Impact factor: 4.153

8.  An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder.

Authors:  D C Goff; T Posever; L Herz; J Simmons; N Kletti; K Lapierre; K D Wilner; C G Law; G N Ko
Journal:  J Clin Psychopharmacol       Date:  1998-08       Impact factor: 3.153

9.  Circadian variations in the plasma concentration of prolactin in the adult male rat.

Authors:  J A Mattheij; J J Swarts
Journal:  J Endocrinol       Date:  1978-10       Impact factor: 4.286

10.  The pharmacokinetics of risperidone in humans: a summary.

Authors:  J Heykants; M L Huang; G Mannens; W Meuldermans; E Snoeck; L Van Beijsterveldt; A Van Peer; R Woestenborghs
Journal:  J Clin Psychiatry       Date:  1994-05       Impact factor: 4.384

View more
  5 in total

Review 1.  Risperidone Induced Hyperprolactinemia: From Basic to Clinical Studies.

Authors:  Milena Stojkovic; Branimir Radmanovic; Mirjana Jovanovic; Vladimir Janjic; Nemanja Muric; Dragana Ignjatovic Ristic
Journal:  Front Psychiatry       Date:  2022-05-06       Impact factor: 5.435

2.  Preclinical investigations into the antipsychotic potential of the novel histamine H3 receptor antagonist GSK207040.

Authors:  Eric Southam; Jackie Cilia; Jane E Gartlon; Marie L Woolley; Laurent P Lacroix; Carol A Jennings; Jane E Cluderay; Charlie Reavill; Claire Rourke; David M Wilson; Lee A Dawson; Andrew D Medhurst; Declan N C Jones
Journal:  Psychopharmacology (Berl)       Date:  2008-09-03       Impact factor: 4.530

3.  Characterization of binding and inhibitory properties of TAK-063, a novel phosphodiesterase 10A inhibitor.

Authors:  Akina Harada; Kazunori Suzuki; Naomi Kamiguchi; Maki Miyamoto; Kimio Tohyama; Kosuke Nakashima; Takahiko Taniguchi; Haruhide Kimura
Journal:  PLoS One       Date:  2015-03-27       Impact factor: 3.240

4.  The distinct effects of subchronic antipsychotic drug treatment on macronutrient selection, body weight, adiposity, and metabolism in female rats.

Authors:  M J Fell; N Anjum; K Dickinson; K M Marshall; L M Peltola; S Vickers; S Cheetham; J C Neill
Journal:  Psychopharmacology (Berl)       Date:  2007-06-21       Impact factor: 4.415

5.  Alstonine as an antipsychotic: effects on brain amines and metabolic changes.

Authors:  Viviane M Linck; Ana P Herrmann; Angelo L Piato; Bernardo C Detanico; Micheli Figueiró; Jorge Flório; Maurice M Iwu; Christopher O Okunji; Mirna B Leal; Elaine Elisabetsky
Journal:  Evid Based Complement Alternat Med       Date:  2011-06-23       Impact factor: 2.629

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.